Parkinson’s disease risk is linked to gut health, researchers say
Those who have had damage to the upper lining of their gastrointestinal tract are 76% more likely to develop Parkinson’s ...
Parkinson's Disease May Start In The Gut, Not The Brain, New Research Says
Parkinson’s disease is a devastating condition that progressively causes trouble with movement, mobility, and speech. But ...
MedPage Today2d
Upper GI Damage Tied to Subsequent Parkinson's Disease
Over a mean follow-up of 14.9 years, Parkinson's diagnoses emerged for 52 patients (2.2%) with upper GI mucosal damage and 48 ...
Eating this salty snack could stave off Parkinson’s disease
Roughly one million Americans are living with Parkinson's disease (PD), a number that is expected to increase to 1.2 million ...
Neuroscience News17h
Are Smokers Really Less Likely to Develop Parkinson’s?
Low doses of carbon monoxide, similar to levels experienced by smokers, can protect against neurodegeneration in Parkinson’s ...
Parkinson’s may begin in the gut, study says, adding to growing evidence
Mucosal damage — an erosion, break or sore in the mucous lining of the GI tract — was associated with a 76 percent greater ...
Neuroscience News1d
Upper GI Damage Linked to 76% Higher Parkinson’s Disease Risk
People with a history of upper gastrointestinal (GI) damage have a 76% higher risk of developing Parkinson’s disease.
Ulcers, damage to upper gastrointestinal tract linked to increased risk of Parkinson's disease
A study led by researchers at Beth Israel Deaconess Medical Center (BIDMC) found the risk of developing Parkinson's disease ...
The Origins Of Parkinson's Disease Have Caused Fierce Debate Among Scientists—But New Research Points To A Breakthrough
A study finds that people with mucosal damage have greater risk of Parkinson’s disease. Here's what to know about the link ...
Impacts5d
Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and ...
Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
Allyx continues to advance clinical research of its first-in-class oral compound for neurodegenerative diseasesNEW HAVEN, ...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a compelling body of evidence from the ...